“A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients With Moderate to Severe Atopic Dermatitis”. 2018. SKIN The Journal of Cutaneous Medicine 2 (S1): S29. https://doi.org/10.25251/skin.2.supp.28.